Lineage Cell Therapeutics Business Summary

Lineage Cell Therapeutics, Inc. (LCTX) is a clinical-stage biotechnology company specializing in the development of allogeneic, "off-the-shelf" cell therapies designed to replace specialized cells lost to degenerative diseases. The company’s revenue model is primarily driven by strategic licensing and collaboration agreements, highlighted by a high-value partnership with Roche and Genentech for its lead candidate, OpRegen. Business operations are organized around four core therapeutic segments: ophthalmology (dry age-related macular degeneration), neurology (spinal cord injury and auditory neuropathy), oncology (lung cancer), and metabolic disorders (Type 1 Diabetes). Within the competitive landscape of regenerative medicine, Lineage maintains a distinct position relative to peers like 4D Molecular Therapeutics, Aura Biosciences, and DBV Technologies by utilizing its proprietary AlloSCOPE manufacturing platform to produce terminally differentiated cells at commercial scale. The executive team is led by CEO Brian Culley, who joined in 2018 from Mast Therapeutics and orchestrated the company’s strategic pivot from its 1990 origins as BioTime, which was originally founded by Dr. Michael West. The current leadership includes CFO Jill Howe, General Counsel George A. Samuel III, and VP of Technical Operations Jennifer Bahr-Davidson, Ph.D., who oversees CMC and quality operations. Corporate development is managed by VP Charlotte Hubbert, Ph.D., a veteran of the Bill & Melinda Gates Foundation’s Strategic Investment Fund. The company is supported by a seasoned board chaired by Michael H. Mulroy and features significant institutional backing from Broadwood Capital—represented by board member Neal Bradsher—as well as major asset managers including BlackRock and Vanguard.